

IN THE CLAIMS:

Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

LISTING OF CLAIMS

1. (Currently Amended) A compound selected from any one of 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:1); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:2); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Asp-NH₂ (SEQ ID NO:3); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Thr-NH₂ (SEQ ID NO:4); 4-amino-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:5); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂ (SEQ ID NO:6); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:7); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:8); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:9); and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂ (SEQ ID NO:10) SEQ ID Nos: 1-10.
2. (Currently Amended) The compound of claim 1, wherein the compound comprises a di- or polyiodinated aromatic modification of a Tyr at position 3 of SEQ ID NOs:1-10.
3. (Currently Amended) The compound of claim 1, wherein a radioactive element is linked to the compound analog.
4. (Original) The compound of claim 3, wherein the radioactive element is selected from the group consisting of ¹⁸⁸Re, ¹⁸⁶Re, scandium-47, copper-67, gallium-72, yttrium-90, iodine-125, iodine-131, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, astatine-211 and bismuth-212.
5. (Currently Amended) The compound of claim 1, wherein the compound analog is linked to a cytotoxic molecule.

6. (Original) The compound of claim 5, wherein the cytotoxic molecule is selected from the group consisting of paclitaxel, doxorubicin or camptothecin.
7. (Original) The compound of claim 1, further comprising a pharmaceutically acceptable carrier.
8. (Currently Amended) A method of visualizing malignant cells in a subject comprising administering to the subject the compound of claim 3, wherein a Tyr at position 3 of SEQ ID NO:1-10 is mono- or polyiodinated.
9. (Previously Presented) A method of treating a cell proliferative disorder in a subject comprising administering to the subject a compound of claim 1.
10. (Original) A method as in claim 9, wherein the cell proliferative disorder comprises a tumor, acromegaly, and/or diabetes.
11. (Original) A compound which selectively binds to SS receptor 2 (SST2) and/or SS receptor 5 (SST5), wherein the compound has a structure selected from the group consisting of (4-Amino)-D-Phe-c [Cys-Tyr-D-Trp-Lys-Val-Cys] -Thr-NH₂, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp- NH₂, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Thr- NH₂, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Asp- NH₂, (4-Amino)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂, and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH₂.
12. (Original) The compound of claim 11, further comprising a radioactive nuclide or a conjugating agent for linking to a cytotoxin.

13. (Previously Presented) A pharmaceutical composition comprising a mixture of a compound of claim 11 and at least one pharmaceutically acceptable carrier.
14. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
15. (Previously Presented) A method of eliciting a somatostatin receptor effect in a mammal in need thereof comprising administering to said mammal an effective amount of a compound according to claim 11 or a pharmaceutically acceptable salt thereof.
16. (Previously Presented) A method of treating prolactin-secreting adenomas, restenosis, diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, nephropathy, gastric acid secretion, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, irritable bowel syndrome, Dumping syndrome, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis, gastrointestinal hormone-secreting tumors, cancer, hepatoma, angiogenesis, inflammatory disorders, arthritis, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding, in a mammal in need thereof, which comprises administering to said mammal a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
17. (Previously Presented) A method of inhibiting the proliferation of *Helicobacter pylori* in a mammal in need thereof, which comprises administering to said mammal a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
18. (Previously Presented) A method of treating prolactin-secreting adenomas, restenosis, diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferation retinopathy, dawn phenomenon, nephropathy, gastric acid secretion, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, irritable

bowel syndrome, Dumping syndrome, watery diarrhea syndrome, AIDS-related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis, gastrointestinal hormone-secreting tumors, cancer, hepatoma, angiogenesis, inflammatory disorders, arthritis, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding, in a mammal in need thereof, which comprises administering to said mammal a compound according to claim 11 or a pharmaceutically acceptable salt thereof.

19. (Previously Presented) A method of inhibiting the proliferation of *Helicobacter pylori* in a mammal in need thereof, which comprises administering to said mammal a compound according to claim 11 or a pharmaceutically acceptable salt thereof.